» Articles » PMID: 26060833

Renal Ischemia/reperfusion Injury; from Pathophysiology to Treatment

Overview
Specialty Nephrology
Date 2015 Jun 11
PMID 26060833
Citations 265
Authors
Affiliations
Soon will be listed here.
Abstract

Ischemia/reperfusion injury (IRI) is caused by a sudden temporary impairment of the blood flow to the particular organ. IRI usually is associated with a robust inflammatory and oxidative stress response to hypoxia and reperfusion which disturbs the organ function. Renal IR induced acute kidney injury (AKI) contributes to high morbidity and mortality rate in a wide range of injuries. Although the pathophysiology of IRI is not completely understood, several important mechanisms resulting in kidney failure have been mentioned. In ischemic kidney and subsequent of re-oxygenation, generation of reactive oxygen species (ROS) at reperfusion phase initiates a cascade of deleterious cellular responses leading to inflammation, cell death, and acute kidney failure. Better understanding of the cellular pathophysiological mechanisms underlying kidney injury will hopefully result in the design of more targeted therapies to prevent and treatment the injury. In this review, we summarize some important potential mechanisms and therapeutic approaches in renal IRI.

Citing Articles

Protective Effects of Phoenixin-14 Administration Against Renal Ischemia/Reperfusion Injury in Rats.

Oz S, Bahar M, Sekerci G, Taslidere A, Tekin S J Biochem Mol Toxicol. 2025; 39(3):e70200.

PMID: 40025799 PMC: 11873675. DOI: 10.1002/jbt.70200.


Myrtenal Pretreatment Exerts a Protective Effect Against Renal Ischemia-Reperfusion Injury in Rats.

Beytur L, Korkmaz E, Kose E, Taslidere A, Tekin S J Biochem Mol Toxicol. 2025; 39(3):e70202.

PMID: 40025781 PMC: 11873678. DOI: 10.1002/jbt.70202.


Critical roles of miR-21 in promotions angiogenesis: friend or foe?.

Saadh M, Jasim N, Ahmed M, Ballal S, Kumar A, Atteri S Clin Exp Med. 2025; 25(1):66.

PMID: 39998742 PMC: 11861128. DOI: 10.1007/s10238-025-01600-7.


Physically engineered extracellular vesicles targeted delivering miR-21-5p to promote renoprotection after renal ischemia-reperfusion injury.

Wu D, Ma W, Wang L, Long C, Chen S, Liu J Mater Today Bio. 2025; 31:101528.

PMID: 39980630 PMC: 11840549. DOI: 10.1016/j.mtbio.2025.101528.


Blood and urinary cytokine balance and renal outcomes at orthopaedic surgery.

McBride W, Kurth M, Watt J, Irvine A, Domanska A, McLean G Front Endocrinol (Lausanne). 2025; 15():1441632.

PMID: 39790288 PMC: 11711776. DOI: 10.3389/fendo.2024.1441632.


References
1.
Gonullu E, Ozkardesler S, Kume T, Duru L, Akan M, Guneli M . Comparison of the effects of dexmedetomidine administered at two different times on renal ischemia/reperfusion injury in rats. Braz J Anesthesiol. 2014; 64(3):152-8. DOI: 10.1016/j.bjane.2013.06.002. View

2.
Zheng X, Zhang X, Sun H, Feng B, Li M, Chen G . Protection of renal ischemia injury using combination gene silencing of complement 3 and caspase 3 genes. Transplantation. 2007; 82(12):1781-6. DOI: 10.1097/01.tp.0000250769.86623.a3. View

3.
Kostenis E, Milligan G, Christopoulos A, Sanchez-Ferrer C, Heringer-Walther S, Sexton P . G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor. Circulation. 2005; 111(14):1806-13. DOI: 10.1161/01.CIR.0000160867.23556.7D. View

4.
Hernandez-Pando R, Schon T, Orozco E, Serafin J, Estrada-Garcia I . Expression of inducible nitric oxide synthase and nitrotyrosine during the evolution of experimental pulmonary tuberculosis. Exp Toxicol Pathol. 2001; 53(4):257-65. DOI: 10.1078/0940-2993-00182. View

5.
Iwai M, Horiuchi M . Devil and angel in the renin-angiotensin system: ACE-angiotensin II-AT1 receptor axis vs. ACE2-angiotensin-(1-7)-Mas receptor axis. Hypertens Res. 2009; 32(7):533-6. PMC: 7091931. DOI: 10.1038/hr.2009.74. View